DAUNOXOME Drug Patent Profile
✉ Email this page to a colleague
When do Daunoxome patents expire, and what generic alternatives are available?
Daunoxome is a drug marketed by Galen (uk) and is included in one NDA.
The generic ingredient in DAUNOXOME is daunorubicin citrate. There are eleven drug master file entries for this compound. Additional details are available on the daunorubicin citrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DAUNOXOME?
- What are the global sales for DAUNOXOME?
- What is Average Wholesale Price for DAUNOXOME?
Summary for DAUNOXOME
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 55 |
| Clinical Trials: | 12 |
| Patent Applications: | 4,495 |
| DailyMed Link: | DAUNOXOME at DailyMed |
Recent Clinical Trials for DAUNOXOME
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Kansas Medical Center | Phase 1 |
| Tara Lin | Phase 1 |
| Vastra Gotaland Region | Phase 3 |
US Patents and Regulatory Information for DAUNOXOME
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galen (uk) | DAUNOXOME | daunorubicin citrate | INJECTABLE, LIPOSOMAL;INJECTION | 050704-002 | Apr 8, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
